Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...
The Food and Drug Administration (FDA) has approved Osvyrti ® (denosumab-desu), a biosimilar to Prolia ® (denosumab), and Jubereq ® (denosumab-desu), a biosimilar to Xgeva ® (denosumab). Osvyrti is ...
The FINANCIAL — Amgen on October 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results